QTTB - Latest News
Q32 Bio Inc. (QTTB), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $238.5M. Trailing twelve-month P/E ratio is 3.34. Beta to the broader market is -0.33.
The article list below shows the most recent QTTB headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent QTTB Headlines
Head to Head Contrast: Q32 Bio (NASDAQ:QTTB) & Applied Therapeutics (NASDAQ:APLT)
defenseworld.net - Oct 12, 2026
Q32 Bio (NASDAQ: QTTB - Get Free Report) and Applied Therapeutics (NASDAQ: APLT - Get Free Report) are both small-cap healthcare companies, but which
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
prnewswire.com - Sep 30, 2026
-- Clinically meaningful efficacy data observed on primary and key secondary endpoints at Week 36 -- -- Robust durability, including maintenance and d
Q32 Bio: Durable Hair Regrowth Remains The Goal
seekingalpha.com - Sep 26, 2026
Q32 Bio'S bempikibart could offer lasting hair regrowth in alopecia areata, but its potential advantage still depends on broader clinical validation.
Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026
prnewswire.com - Sep 21, 2026
-- Late-breaking oral and poster presentations to feature additional 36-week results and initial findings from the 16-week off-drug period from Part B
Q32 Bio Inc. (QTTB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com - Sep 15, 2026
Q32 Bio Inc.
How News Affects QTTB Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track QTTB's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked QTTB news questions
- What is the latest QTTB news headline?
- The most recent QTTB headline (Oct 12, 2026) is "Head to Head Contrast: Q32 Bio (NASDAQ:QTTB) & Applied Therapeutics (NASDAQ:APLT)". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the QTTB news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What QTTB news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual QTTB options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.